The spin-off helmed by Aleix Prat received the award in the category of Collaborative Research in Transfer for Development for its HER2DX breast canc1
HER2DX® was highlighted in Times 'Medical Care' category, which publicizes inventions that are successfully implemented in medical practice.
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
Aleix Prat is leading the research, which focuses on discovering new ways of diagnosing hormone receptor-positive breast cancer, as well as new thera1
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
A study conducted at Hospital Clínic analysed the genetic profile of more than 300 patients with solid tumours using a liquid biopsy blood test, resu1
The Hospital Clínic Medical Oncology Service, led by Dr. Aleix Prat, has launched a home infusion programme for solid organ cancer patients and immun1
Researchers from Hospital Clínic-IDIBAPS have shown for the first time that the benefit of chemotherapy in premenopausal patients with low-risk hormo1
The ACROPOLI clinical trial is being launched. It is a pioneering, nationwide research study that aims to assess the efficacy of immunotherapy in 291
